Renal dysfunction associated with clinical response to intravitreal conbercept therapy for diabetic macular edema

Wei Wu, Huidong Liu, Xue Xiao, Yaxin Wang, Songfu Feng, Jiaqi Liu, Yong-gang YuanInternational Journal of Ophthalmology 2025 · DOI

This study, published in the International Journal of Ophthalmology, explores the intersection of systemic health and ocular therapy. Specifically, it investigates how a patient's kidney function influences their response to conbercept—a common anti-VEGF (Vascular Endothelial Growth Factor) treatment—for Diabetic Macular Edema (DME).

TL;DR

The study demonstrates that renal health is a significant predictor of how well patients with diabetic macular edema respond to conbercept injections. Patients with higher kidney function (eGFR) and higher hemoglobin levels achieved significantly better anatomical outcomes (macular thinning), suggesting that systemic metabolic health is a critical factor in the success of localized eye treatments.

What Problem Does This Paper Address?

Diabetic Macular Edema (DME) is a primary cause of vision loss in diabetic patients, characterized by fluid leakage in the retina. While intravitreal injections of anti-VEGF agents like conbercept are the gold standard for treatment, clinical response is highly variable.

The authors address a critical gap: why do some patients respond poorly to treatment despite consistent dosing? Given that diabetic retinopathy and diabetic nephropathy (kidney disease) share similar microvascular pathways, the researchers hypothesized that a patient’s renal status might serve as a biomarker for their ocular treatment prognosis.

Methods

The researchers conducted a retrospective study of 100 eyes from 100 patients treated with conbercept (IVC) using a "3+PRN" regimen (three initial monthly doses followed by injections as needed).

Key Categorization: Patients were divided into three groups based on their estimated glomerular filtration rate (eGFR):

  1. Normal renal function: eGFR $\ge 90$ mL/min/1.73 m²
  2. Impaired renal function: $60 \le$ eGFR $< 90$ mL/min/1.73 m²
  3. Renal insufficiency: eGFR $< 60$ mL/min/1.73 m²

Analytical Approach: The team used Ridge regression analysis. This is a specialized statistical technique used when independent variables (like blood urea nitrogen and creatinine) are highly correlated (collinearity), allowing the researchers to isolate the specific impact of renal function on visual and anatomical outcomes.

Datasets

The study utilized a real-world clinical dataset from two major hospitals in Guangzhou, China (Guangzhou Red Cross Hospital and Zhujiang Hospital), covering patients treated between January 2018 and September 2023. Data points included:

  • Systemic markers: BUN, serum creatinine, uric acid, HbA1c, and hemoglobin.
  • Ocular markers: Best-corrected visual acuity (BCVA) and central subfield macular thickness (CST) measured via Spectral-Domain Optical Coherence Tomography (SD-OCT).

Key Insights and Ideas

  • The Kidney-Eye Axis: The most striking insight is that the eye is not an island. Systemic renal dysfunction acts as a "risk factor" for poor drug efficacy. Lower eGFR was strongly associated with a failure to reduce macular thickness effectively.
  • Hemoglobin as a Co-factor: Higher hemoglobin levels were associated with better anatomical responses. The authors suggest that anemia-induced hypoxia might stimulate the release of more VEGF, essentially "fighting against" the conbercept treatment.
  • The "Ceiling Effect" in Vision: Interestingly, while kidney function predicted anatomical success (thinning of the retina), functional success (vision improvement) was more strongly predicted by baseline vision. Patients with worse vision at the start had more "room" to improve, regardless of their kidney status.
  • Predictive Value: Evaluating renal function before starting IVC therapy could help doctors set realistic expectations for patients and potentially adjust treatment frequency.

Key Results

  • Overall Efficacy: Across all groups, conbercept was effective. Mean BCVA improved from 0.81 to 0.72 logMAR, and mean CST decreased from 427.85 $\mu$m to 275.31 $\mu$m ($P < 0.001$).
  • Anatomical Response: The normal renal function group showed superior anatomical outcomes. Ridge regression confirmed that higher eGFR ($P < 0.001$), higher hemoglobin ($P = 0.032$), and thicker baseline CST ($P = 0.017$) were the primary predictors of macular edema retrogression.
  • Injection Frequency: Patients in the renal insufficiency group required more injections on average (2.40) compared to the normal group (1.99) to achieve results, highlighting a higher treatment burden for those with poor kidney health.

Limitations and Future Work

  • Retrospective Nature: As a retrospective study, it relies on existing medical records, which may have inherent biases compared to a prospective, randomized controlled trial.
  • Sample Size: With only 100 patients, the study is relatively small. The authors note that the number of patients in certain subgroups (like different stages of diabetic retinopathy) was too small for detailed sub-analysis.
  • Short Follow-up: The mean follow-up was 3.9 months. Long-term studies are needed to see if these renal markers predict treatment "burnout" or long-term resistance to anti-VEGF therapy.
  • Future Directions: The authors suggest that future research should focus on whether improving a patient's systemic renal and hemoglobin status can directly "boost" the efficacy of ocular injections.

Summary updated

Abstract

Our results indicate that the renal dysfunction is the risk factor associated with the efficacy of IVC for DME.
BibTeX
@article{wu2025renal,
  author = {Wei Wu and Huidong Liu and Xue Xiao and Yaxin Wang and Songfu Feng and Jiaqi Liu and Yong-gang Yuan},
  title = {{Renal dysfunction associated with clinical response to intravitreal conbercept therapy for diabetic macular edema}},
  journal = {International Journal of Ophthalmology},
  year = {2025},
  doi = {10.18240/ijo.2025.03.12},
}
Figure